The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Open accessAbstract
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. Methods: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. Results: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). Conclusions: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, treatment of patients with lymphoproliferative malignancies with inhibitors of BTK has resulted in a surge in cases of invasive aspergillosis (79, 264).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [264]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,465
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 3×
“Ibrutinib was approved by the US Food and Drug Administration for the treatment of patients with CLL, previously treated mantle cell lymphoma (MCL) or marginal zone lymphoma, WM, or refractory chronic graft-versus-host disease, and by the European Medicines Agency for the treatment of patients with CLL, WM, or previou…”
MethodIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D. L., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 951
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes
Thomas, J. D., Sideras, P., Smith, C. I. E., Vořechovský, I., Chapman, V. M., & Paul, W. E. (1993) · Science · doi:10.1126/science.8332900 · Cited by 613
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520
Research works printed but not linked: 1
- Smith, 1993–2018, X-linked agammaglobulinemia
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 274
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
(ECIL), O. B. O. T. E. C. O. I. I. L., Maschmeyer, G., Greef, J. D., Mellinghoff, S. C., Nosari, A., Thiébaut, A., Bergeron, A., Franquet, T., Blijlevens, N. M. A., & Maertens, J. A. (2019) · Leukemia · doi:10.1038/s41375-019-0388-x · Cited by 188
Managing toxicities of Bruton tyrosine kinase inhibitors
Lipsky, A. H., & Lamanna, N. (2020) · Hematology · doi:10.1182/hematology.2020000118 · Cited by 174
Mucormycosis of the Central Nervous System
Chikley, A., Ben‐Ami, R., & Kontoyiannis, D. P. (2019) · Journal of Fungi · doi:10.3390/jof5030059 · Cited by 143
Dreger, P., Ghia, P., Schetelig, J., van Gelder, M., Kimby, E. K., Michallet, M., Moreno, C., Robak, T., Stilgenbauer, S., & Montserrat, E. (2018) · Blood · doi:10.1182/blood-2018-01-826008 · Cited by 105
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Chen, L. S., Bose, P., Cruz, N. D., Jiang, Y., Wu, Q., Thompson, P. A., Feng, S., Kroll, M. H., Qiao, W., Huang, X., et al. (2018) · Blood · doi:10.1182/blood-2018-06-860593 · Cited by 105
Rendeiro, A. F., Krausgruber, T., Fortelny, N., Zhao, F., Penz, T., Farlik, M., Schuster, L. C., Nemc, A., Tasnády, S., Réti, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14081-6 · Cited by 97
Morjaria, S. M., Frame, J., Franco-Garcia, A., Geyer, A. I., Kamboj, M., & Babady, N. E. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1072 · Cited by 92
Teh, B. W., Yeoh, D. K., Haeusler, G. M., Yannakou, C. K., Fleming, S. A., Lindsay, J., & Slavin, M. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15588 · Cited by 89
The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia
Apostolopoulou, A., & Fishman, J. A. (2022) · Journal of Fungi · doi:10.3390/jof8111167 · Cited by 89
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Rogers, K. A., Mousa, L., Zhao, Q., Bhat, S. A., Byrd, J. C., Boghdadly, Z. E., Guerrero, T., Levine, L. B., Lucas, F. M., Shindiapina, P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0481-1 · Cited by 90
Thibaud, S., Tremblay, D. A., Bhalla, S., Zimmerman, B. S., Sigel, K. M., & Gabrilove, J. L. (2020) · British Journal of Haematology · doi:10.1111/bjh.16863 · Cited by 84
Ruchlemer, R., Ben‐Ami, R., Bar‐Meir, M., Brown, J. R., Malphettes, M., Mous, R., Tonino, S. H., Soussain, C., Barzic, N., Messina, J. A., et al. (2019) · Mycoses · doi:10.1111/myc.13001 · Cited by 82
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma, M., Mulder, T. A., & Österborg, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686768 · Cited by 83
Nucci, M., & Anaissie, E. J. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00159-22 · Cited by 79
Mauro, F. R., Giannarelli, D., Galluzzo, C. M., Vitale, C., Visentin, A., Riemma, C., Rosati, S., Porrazzo, M., Pepe, S., Coscia, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0884-z · Cited by 79
Invasive Pulmonary Aspergillosis
Ledoux, M., & Herbrecht, R. (2023) · Journal of Fungi · doi:10.3390/jof9020131 · Cited by 81
Liévin, R., Blasi, R. D., Morin, F., Galli, E., Allain, V., de Jorna, R., Vercellino, L., Parquet, N., Mebarki, M., Larghero, J., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01526-0 · Cited by 73
Mucosal IgA Prevents Commensal Candida albicans Dysbiosis in the Oral Cavity
Millet, N., Solis, N. V., & Swidergall, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.555363 · Cited by 73
Robak, T., Witkowska, M., & Smolewski, P. (2022) · Cancers · doi:10.3390/cancers14030771 · Cited by 68
Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies
Pardo, E., Lemiale, V., Mokart, D., Stoclin, A., Moreau, A., Kerhuel, L., Calvet, L., Valade, S., JONG, A. D., Darmon, M., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05789-6 · Cited by 67
Second cancer incidence in CLL patients receiving BTK inhibitors
Bond, D. A., Huang, Y., Fisher, J. L., Ruppert, A. S., Owen, D. H., Bertino, E. M., Rogers, K. A., Bhat, S. A., Grever, M. R., Jaglowski, S. M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0987-6 · Cited by 67
Menacing Mold: Recent Advances in Aspergillus Pathogenesis and Host Defense
Tischler, B. Y., & Hohl, T. M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.027 · Cited by 57
Self-citationMorrissey, C. O., Kim, H. Y., Duong, T.-M. N., Moran, E., Alastruey‐Izquierdo, A., Denning, D. W., Perfect, J. R., Nucci, M., Chakrabarti, A., Rickerts, V., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myad129 · Cited by 61
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia
Banerjee, P., Zhang, R., Ivan, C., Galletti, G., Clise-Dwyer, K., Barbaglio, F., Scarfò, L., Aracil, M., Klein, C., Wierda, W. G., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0152 · Cited by 54
Shariati, A., Moradabadi, A., Chegini, Z., Khoshbayan, A., & Didehdar, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s254478 · Cited by 58
Liposomal amphotericin B—the present
Maertens, J. A., Pagano, L., Azoulay, É., & Warris, A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac352 · Cited by 61
Why are so many cases of invasive aspergillosis missed?
Danion, F., Rouzaud, C., Dureault, A., Poirée, S., Bougnoux, M., Alanio, A., Lanternier, F., & Lortholary, O. (2018) · Medical Mycology · doi:10.1093/mmy/myy081 · Cited by 54
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Little, J. S., Weiss, Z., & Hammond, S. P. (2021) · Journal of Fungi · doi:10.3390/jof7121058 · Cited by 55
Bergamasco, M. D., Pereira, C. A. P., Arrais‐Rodrigues, C., Ferreira, D. B., Baiocchi, O. C. G., Kerbauy, F. R., Nucci, M., & Colombo, A. L. (2021) · Journal of Fungi · doi:10.3390/jof7080588 · Cited by 50
Fiorcari, S., Maffei, R., Vallerini, D., Scarfò, L., Barozzi, P., Maccaferri, M., Potenza, L., Ghia, P., Luppi, M., & Marasca, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02158 · Cited by 54
Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Ruíz-Camps, I. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936121989548 · Cited by 48
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Kamboj, M., & Shah, M. K. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.02.007 · Cited by 50
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Zarakas, M. A., Desai, J. V., Chamilos, G., & Lionakis, M. S. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00343-9 · Cited by 51
Terpos, E., Gavriatopoulou, M., Fotiou, D., Giatra, C., Asimakopoulos, I., Dimou, M., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Darmani, I., Briasoulis, Α., et al. (2021) · Cancers · doi:10.3390/cancers13174480 · Cited by 45
Ryan, C. E., Cheng, M. P., Issa, N. C., Brown, J. R., & Davids, M. S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001678 · Cited by 48
Miesel, L., Cushion, M. T., Ashbaugh, A., Lopez, S. R., & Ong, V. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01992-20 · Cited by 47
Langerbeins, P., & Eichhorst, B. F. (2021) · Acta Haematologica · doi:10.1159/000514071 · Cited by 45
Targeting ITK signaling for T cell-mediated diseases
Weeks, S., Harris, R., & Karimi, M. A. (2021) · iScience · doi:10.1016/j.isci.2021.102842 · Cited by 43
Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease
Ward, R., Aghaeepour, N., Bhattacharyya, R. P., Clish, C. B., Gaudilliere, B. L., Hacohen, N., Mansour, M. K., Mudd, P. A., Pasupneti, S., Presti, R. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab483 · Cited by 45
Tapaninen, T., Olkkola, A. M., Tornio, A., Neuvonen, M., Elonen, E., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12716 · Cited by 46
Gavriatopoulou, M., Terpos, E., Ntanasis‐Stathopoulos, I., Briasoulis, Α., Gumeni, S., Malandrakis, P., Fotiou, D., Migkou, M., Theodorakakou, F., Eleutherakis‐Papaiakovou, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005444 · Cited by 42
Huang, S., Wu, A. Y.-J., Lee, S. S., Huang, Y., Lee, C.-Y., Yang, T.-L., Wang, H.-W., Chen, H.-J., Chen, Y. C., Ho, T., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.12.004 · Cited by 44
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Maffei, R., Maccaferri, M., Arletti, L., Fiorcari, S., Benatti, S., Potenza, L., Luppi, M., & Marasca, R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100635 · Cited by 43
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Galimberti, S., Baldini, C., Baratè, C., Ricci, F., Balducci, S., Grassi, S., Ferro, F., Buda, G., Benedetti, E., Fazzi, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104866 · Cited by 41
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Aspergillosis: Emerging risk groups in critically ill patients
Kluge, S., Strauß, R., Kochanek, M., Weigand, M. A., Rohde, H., & Lahmer, T. (2021) · Medical Mycology · doi:10.1093/mmy/myab064 · Cited by 41
BTK drives neutrophil activation for sterilizing antifungal immunity
Desai, J. V., Zarakas, M. A., Wishart, A. L., Roschewski, M. J., Aufiero, M. A., Donkó, Á., Wigerblad, G., Shlezinger, N., Plate, M., James, M. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176142 · Cited by 40
Self-citationInfectious disease considerations in immunocompromised patients
McGrath, B. A., Broadhurst, M., & Roman, C. (2020) · JAAPA · doi:10.1097/01.jaa.0000694948.01963.f4 · Cited by 36
Ahmed, K. R., Rahman, M. M., Islam, M. N., Fahim, M. M. H., Rahman, M. A., & Kim, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116497 · Cited by 34
Ball, S., Das, A., Vutthikraivit, W., Edwards, P. J., Hardwicke, F. L., Short, N. J., Borthakur, G. M., & Maiti, A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.10.004 · Cited by 31
Frei, M., Aitken, S. L., Jain, N., Thompson, P. A., Wierda, W. G., Kontoyiannis, D. P., & DiPippo, A. J. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1775215 · Cited by 31
Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents
Bernardes, M., & Hohl, T. M. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00154-4 · Cited by 34
Self-citationChu, S., McCormick, T. S., Lazarus, H. M., Leal, L. O., & Ghannoum, M. A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108731 · Cited by 30
Tavakoli, G. M., Yazdanpanah, N., & Rezaei, N. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00401-y · Cited by 33
Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., et al. (2021) · Cancers · doi:10.3390/cancers13133240 · Cited by 27
Gold, J. A. W., Tolu, S. S., Chiller, T. M., Benedict, K., & Jackson, B. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1026 · Cited by 25
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Tettamanti, S., Rotiroti, M. C., Attianese, G. M. P. G., Arcangeli, S., Zhang, R., Banerjee, P., Galletti, G., McManus, S. D., Mazza, M., Nicolini, F., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2043299 · Cited by 26
Mancuso, S., Mattana, M., Carlisi, M., Santoro, M., & Siragusa, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063368 · Cited by 27
Pagano, L., & Facchinelli, D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.063 · Cited by 23
Teh, B. W., Chui, W. C. M., Handunnetti, S. M., Tam, C. S. L., Worth, L. J., Thursky, K., & Slavin, M. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1543884 · Cited by 23
Invasive Aspergillosis in Patients Treated With Ibrutinib
Fürstenau, M., Simon, F., Cornely, O. A., Hicketier, T., Eichhorst, B. F., Hallek, M. J., & Mellinghoff, S. C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000309 · Cited by 23
Pouvaret, A., Guéry, R., Montillet, M., Molina, T. J., Dureault, A., Bougnoux, M., Galliot, R., Lanternier, F., Delarue, R., & Lortholary, O. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.01.016 · Cited by 23
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS‐CoV‐2 Pandemic
Rossi, D., Shadman, M. S., Condoluci, A., Brown, J. R., Byrd, J. C., Gaïdano, G., Hallek, M. J., Hillmen, P., Mato, A. R., Montserrat, E., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000432 · Cited by 22
Alkharabsheh, O. A., Alsayed, A., Morlote, D. M., & Mehta, A. (2021) · Current Oncology · doi:10.3390/curroncol28010081 · Cited by 22
Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections
Bechman, K., Galloway, J. B., & Winthrop, K. L. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00350-w · Cited by 22
Cryptococcosis Associated With Biologic Therapy: A Narrative Review
Li, X., Paccoud, O., Chan, K. H., Yuen, K., Manchon, R., Lanternier, F., Slavin, M. A., van de Veerdonk, F. L., Bicanic, T. A., & Lortholary, O. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae316 · Cited by 21
Pidala, J. A., Kim, J., Kalos, D., Cutler, C. S., DeFilipp, Z. M., Flowers, M. E. D., Hamilton, B. K., Chin, K., Rotta, M., Jurdi, N. E., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014374 · Cited by 21
Dalal, N., Dores, G. M., Curtis, R. E., Linet, M. S., & Morton, L. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16492 · Cited by 21
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
Allouchery, M., Tomowiak, C., Lombard, T., Pérault‐Pochat, M., & Salvo, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.769315 · Cited by 21
Infections in patients with chronic lymphocytic leukemia
Guaraná, M., & Nucci, M. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.05.006 · Cited by 21
Ibrutinib in CLL/SLL: From bench to bedside (Review)
Zi, F., Li, Y., Shi, Q., Tang, A., & Cheng, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7364 · Cited by 21
Infante, M. S., Fernández‐Cruz, A., Núñez, L., Carpio, C. D. C., Ubieto, A. J., López‐Jiménez, J., Vásquez, L., Campo, R. D., Romero, S., Alonso, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4293 · Cited by 20
Avalon, J. C., Fuqua, J. L., Miller, T. C., Deskins, S. J., Wakefield, C., King, A., Inderbitzin-Brooks, S., Bianco, C. M., Veltri, L. W., Fang, W., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00125-8 · Cited by 19
Mikulska, M., Oltolini, C., Zappulo, E., Bartoletti, M., Frustaci, A. M., Visentin, A., Vitale, C., & Mauro, F. R. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101180 · Cited by 20
Non‐Aspergillus invasive mould infections in patients treated with ibrutinib
Anastasopoulou, A. N., DiPippo, A. J., & Kontoyiannis, D. P. (2020) · Mycoses · doi:10.1111/myc.13120 · Cited by 20
Prezzo, A., Cavaliere, F. M., Bilotta, C., Pentimalli, T. M., Iacobini, M., Cesini, L., Foà, R., Mauro, F. R., & Quinti, I. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106233 · Cited by 19
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Nocco, S. E., Andriano, T. M., Bose, A., Chilov, M., Godwin, K., Dranitsaris, G., Wu, S., Lacouture, M. E., Roeker, L. E., Mato, A. R., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103696 · Cited by 21
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib
Cummins, K. C., Cheng, M. P., Kubiak, D. W., Davids, M. S., Marty, F. M., & Issa, N. C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485913 · Cited by 19
Song, X., Rao, H., Guo, C., Yang, B., Ren, Y., Wang, M., Li, Y., Cao, Z., & Pei, J. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153802 · Cited by 19
Odeny, T., Fink, V. I., Muchengeti, M. M., & Gopal, S. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.06.007 · Cited by 18
Majumdar, A., Shah, M. R., Park, J. J., Narayanan, N., Kaye, K. S., & Bhatt, P. J. (2023) · Antibiotics · doi:10.3390/antibiotics12030592 · Cited by 18
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Dousa, K. M., Babiker, A., Aartsen, D. V., Shah, N. B., Bonomo, R. A., Johnson, J. L., & Skalweit, M. J. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy168 · Cited by 18
Ohmoto, A., & Fuji, S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100738 · Cited by 18
Infections associated with the new ‘nibs and mabs’ and cellular therapies
Maus, M. V., & Lionakis, M. S. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000656 · Cited by 19
The Right Dose: From Phase I to Clinical Practice
Groenland, S. L., Ratain, M. J., Chen, L. S., & Gandhi, V. V. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_319567 · Cited by 17
Marchesini, G., Nadali, G., Facchinelli, D., Candoni, A., Cattaneo, C. M., Laurenti, L., Fanci, R., Farina, F., Lessi, F., Visentin, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17145 · Cited by 17
Chilson, E. L., Scott, D. A., Schmöele-Thoma, B., Watson, W. K., Moran, M. M., & Istúriz, R. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735224 · Cited by 16
Zinzani, P. L., Rambaldi, A., Gaïdano, G., Girmenia, C., Marchetti, M., Pane, F., Tura, S., & Barosi, G. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.04.016 · Cited by 16
Fehr, M., Cathomas, G., Graber, A., Makert, E., Gaus, E., & Boggian, K. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.12.005 · Cited by 16
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Makita, S., Hosoba, R., & Tobinai, K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1802424 · Cited by 17
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 18
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
Brochard, J., Morio, F., Mahé, J., Pape, P. L., Guimard, T., Mahé, B., Leterrier, M., Morrier, M., Raffi, F., & Boutoille, D. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.07.005 · Cited by 16
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
Rey-Barroso, J., Munaretto, A., Rouquié, N., Mougel, A., Chassan, M., Gadat, S., Dewingle, O., Poincloux, R., Cadot, S., Ysebaert, L., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282466 · Cited by 16
Higuita, N. I. A., Chastain, D. B., Scott, B., Sahra, S., Barahona, L. V., Henao-Cordero, J., Lee, A. L.-H., Tuells, J., & Henao‐Martínez, A. F. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae115 · Cited by 15
Vargas-Blanco, D. A., Hepworth, O. W., Basham, K. J., Simaku, P., Crossen, A. J., Timmer, K. D., Hopke, A. R., Brown, H. E., Vandal, S. R., Jensen, K. N., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176162 · Cited by 16
Eichenberger, E. M., Saullo, J. L., Brander, D. M., Wang, S. J., Perfect, J. R., & Messina, J. A. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.12.007 · Cited by 15
Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
Sittig, K. R., Laageide, L. G., Akhtar, Z., Wall, G. C., & Kumar, S. C. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01120 · Cited by 15
Metadata
- Authors
- Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-27
- Volume
- 67
- Issue
- 5
- Pages
- 687-692
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6093991
- OpenAlex
- W2789508123
- Cited by
- 271
- References
- 36
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 25 · 2022: 26 · 2021: 50 · 2020: 56 · 2019: 36 · 2018: 15
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30 CA008748)
- National Institutes of Health (K08 CA184038)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- ibrutinib, serious infections, lymphoid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, BTK inhibitors, invasive fungal infections, invasive bacterial infection, infection risk factors, opportunistic infections
- MeSH terms
- Invasive Fungal Infections, Adenine, Adult, Aged, Aged, 80 and over, Bacterial Infections, Female, Humans, Lymphopenia, Male, Middle Aged, New York, Opportunistic Infections, Piperidines, Pyrazoles, Pyrimidines, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Young Adult, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
